HealthQuill Drugs
The USFDA has approved two treatments for sickle cell disease, one of them the first in the US based on gene-editing technology.
Drugs Health Pharma

US drug regulator approves two treatments for sickle cell disease 

HQ Team December 8, 2023: The USFDA has approved two treatments for sickle cell disease, one of them the first in the US.

Read More
The current global risk from cholera is “very high” with vaccines running short of demand, the World Health Organization stated.
Drugs Health Pharma

WHO maintains global cholera risk at “very high” category

HQ Team December 8, 2023: The current global risk from cholera is “very high” with vaccines running short of demand, the World Health.

Read More
AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to boost the North Chicago, Illinois-based company’s presence in the psychiatric and neurological disorder segment.
Drugs Health Pharma

AbbVie to acquire Cerevel for $8.7b to bolster neurological treatments

HQ Team December 7, 2023: AbbVie Inc., will buy Cerevel Therapeutics, developing drugs for neuroscience diseases, for $8.7 billion in a bid to.

Read More
Junior hospital doctors, who make up about half of the National Health Service (NHS) medical workforce in England, are going on the longest strike in NHS history around Christmas and January after pay talks with the government failed.
Drugs Health Pharma

UK’s junior NHS doctors to strike around Christmas, pay talks fail 

HQ Team December 6, 2023: Junior hospital doctors, who make up about half of the National Health Service (NHS) medical workforce in England,.

Read More
Pneumonia is a form of acute respiratory infection that affects the lungs and kills more children than any other infectious disease. Every day at least one child dies from pneumonia every 43 seconds, according to UNICEF.
Drugs Health Pharma

Opinion: Steps for prevention, spread, and monitoring pneumonia

By K. Leelamoni November 5, 2023: Outbreaks of pneumonia affecting children in parts of northern China, the US,  the Netherlands, and Denmark are higher than.

Read More
Fluorescent staining reveals the extensive network of blood vessels of the dura mater. These vessels contain T cells that, in a mouse model of chronic high blood pressure, become activated and produce conditions that can lead to dementia-like symptoms.Image courtesy of the Iadecola lab.
Drugs Health Pharma

Abnormal brain cell activation in high BP patients linked to dementia

HQ Team December 5, 2023: The response of immune cells inside the protective covering of the brain may lead to a cognitive decline.

Read More
US-based Pacific Northwest National Laboratory, Microsoft Corp., and Micron Technology have joined hands to make computational chemistry available to researchers and industrial users.
Drugs Health Pharma

Roche forays into weight-loss therapy, buys Carmot for $2.7 billion

HQ Team December 4, 2023: In a strategic push into the obesity and diabetes treatment market, Roche, a leading pharmaceutical company, has finalized.

Read More
Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood cancer drug Jaypirca.
Drugs Health Pharma

Eli Lilly’s drug gets second FDA nod for treating blood cancer in adults

HQ Team December 4, 2023: Eli Lilly and Company got a second accelerated approval from the Food and Drug Administration for its blood.

Read More
Semaglutide based weightloss drugs tied to increased suicide risk in a new study
Drugs Health Pharma

EMA expands probe into suicidal thoughts linked to weight loss drugs

HQ Team December 2, 2023: The European Medicines Agency (EMA) is intensifying its investigation into the potential link between certain GLP-1 receptor agonist.

Read More
Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50% of the patients opted out due to adverse effects of the medicine.
Drugs Health Pharma

Pfizer Inc., stops twice-daily oral obesity drug trial at mid-stage

HQ Team December 2, 2023: Pfizer Inc., has discontinued its clinical trials of the twice-daily oral weight-loss drug, danuglipron, after more than 50%.

Read More